Zevra Therapeutics (ZVRA) Stock: Buy, Sell, or Hold?
ZVRA - Zevra Therapeutics, Inc. Common Stock
$9.99
-0.19 (-1.87%)
▼
5d:
-9.51%
30d:
-18.78%
90d:
-28.49%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When ZVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ZVRA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ZVRA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.15
Based on -1.9% avg growth
INTRINSIC VALUE TODAY
$6.30
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZVRA is currently trading at $9.99, which is considered oversold relative to its 30-day fair value range of $11.36 to $12.20. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.3) compared to its historical average (10.4). Remarkably, the market is currently pricing in an annual earnings decline of 3.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZVRA is in a uptrend. The price is currently testing key support at $9.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ZVRA scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+150.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZVRA is in a uptrend. The price is currently testing key support at $9.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ZVRA scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+150.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.36 -
$12.20
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding ZVRA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 150.3% below Wall St target ($25.00)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.36 -
$12.20
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$9.85
Resistance Level
$11.88
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.28
Wall Street Target
$25.00
(+150.3%)
Revenue Growth (YoY)
53.3%
Earnings Growth (YoY)
-88.4%
Profit Margin
42.8%
Valuation Discount vs History
-3.7% cheaper
PE vs Historical
9.3 vs 10.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.7%
(market-implied from PE analysis)
1-Year Target
$9.62
(-4%)
2-Year Target
$9.26
(-7%)
3-Year Target
$8.92
(-11%)
3-Yr Target (if PE normalizes)
(PE: 9→10)
$10.00
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: -7.7%)
$17.26
(+73%)
Base:
(SPY PE: 9.3, Growth: -7.7%)
$7.85
(-21%)
Bear:
(PE: 7.9, Growth: -7.7%)
$6.67
(-33%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (11x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 10.95 | Current EPS (TTM): $0.93
Bull Case
$12.96
(+30%)
Analyst growth 15.8%, PE expands to 12.0
Base Case
$11.79
(+18%)
Market implied 15.8%, PE stable at 11.0
Bear Case
$6.92
(-31%)
Severe decline -20.0%, PE contracts to 9.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.3 to 10.4
Stabilization Target:
$11.20
(+12.1%)
PE Expansion Potential:
+12.1%
Share & Embed Analysis
Last updated: October 03, 2026 9:35 AM ET
Data refreshes hourly during market hours. Next update: 10:35 AM
Data refreshes hourly during market hours. Next update: 10:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 52 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 68 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$107 | 67 BUY |
Advanced ZVRA Option Strategies
Professional options setups generated by AI based on today's ZVRA price and gamma walls.
